Supplementary Table 3: GWAS summary statistics used to test genetic correlations with treatment-resistant depression (TRD) and non-TRD using linkage disequilibrium score regression (LDSC) in UKB. ADHD=attention deficit hyperactivity disorder; ASD=autism spectrum disorders;

Trait	Type of	N cases	N controls	Ethnicity	Reference
	phenotype				(PubMed ID)
Psychiatric disorders	•				
Major depressive	Binary	45,591	97,674	European	29700475
disorder*^					
Depressive	Continuous	105,739		European	27089181
symptoms					
	Binary	16,471	58,656		
Bipolar disorder^	Binary	20,352	31,358	European	31043756
Schizophrenia	Binary	36,989	113,075	European	25056061
ADHD	Continuous	17,666		European	27663945
ASD	Binary	18,381	27,969	European	30804558
Anorexia nervosa^	Binary	16,992	55,525	European	31308545
PGC cross-disorder	Binary	33,332	27,888	European	23453885
study					
Personality and relat	ted traits				
Neuroticism	Continuous	170,911		European	27089181
Openness to	Continuous	17,375		European	21173776
experience					
Consciousness	Continuous	17,375		European	21173776
Subjective	Continuous	298,420		European	27089181
wellbeing					
Sleep-related traits	1				T
Insomnia	Binary	32,155	26,973	European	27992416
Sleep duration	Continuous	128,266		European	27494321
Chronotype	Continuous	128,266		European	27494321
(morningness)					
Cognitive and relate					I
Childhood IQ	Continuous	17,989		European	23358156
Intelligence	Continuous	78,308		European	28530673
Years of schooling	Continuous	293,723		European	27225129
College completion	Continuous	126,559		European	23722424
Cardio-metabolic an	d related traits				T
LDL cholesterol	Continuous	95,454		European	20686565
HDL cholesterol	Continuous	99,900		European	20686565
Triglycerides	Continuous	96,598		European	20686565
Type 2 diabetes	Binary	34,840	114,981	European	22885922
Coronary artery	Binary	60,801	123,504	European and	26343387
disease				south Asian	
Ever smoked	Binary	41,951	32,102	European	20418890
Obesity class 1	Binary	55,229	104,894	European	23563607
Obesity class 2	Binary	15,334	97,858	European	23563607
Obesity class 3	Binary	3,986	67,010	European	23563607
BMI	Continuous	249,796		European	20935630
Waist-to-hip ratio	Continuous	224,459		European	25673412

^{*} Subjects from UK Biobank and 23AndMe were excluded

^ The genetic correlations with the TRD phenotypes were not estimated using LD Hub for these traits but using the software on a local machine because of the availability of significantly smaller datasets on LD Hub compared to the most recent studies

Definitions of obesity:

Obesity class 1: BMI ≥30 kg/m2 Obesity class 2: BMI ≥35 kg/m2 Obesity class 3: BMI ≥40 kg/m2

Supplementary Table 4: GWAS summary statistics used to create the polygenic risk scores (PRSs) in UKB and EXCEED (in EXCEED only PRS for major depressive disorder, schizophrenia and bipolar disorder were tested for association with depression defined using primary care data).

Trait	Type of phenotype	N cases	N controls	Ethnicity	Reference (PubMed ID)		
Psychiatric disorders							
Major depressive disorder*	Binary	45,591	97,674	European	29700475		
Schizophrenia	Binary	36,989	113,075	European	25056061		
Bipolar disorder	Binary	20,352	31,358	European	31043756		
Attention-deficit	Binary	20,183	35,191	European	30478444		
hyperactivity							
disorder							
Personality and relat	ted traits						
Neuroticism	Continuous	63,030		European	25993607		
Subjective	Continuous	298,420		European	27089181		
wellbeing**							
Cognitive traits	Cognitive traits						
Intelligence	Continuous	269,867		European	29942086		
Childhood IQ	Continuous	12,441		European	23358156		

^{*} Subjects included in UK Biobank and 23AndMe were excluded from the analyses

^{** 4,876} participants from UK Biobank were included in both this previous study and the present one

Supplementary Table 5: **(A)** results of the association analyses between the PRS of major depressive disorder (MDD), bipolar disorder and schizophrenia with depression diagnosis in UK Biobank primary care data (at least two or more diagnostic codes or at least one diagnostic code). For each measure of MDD, the number of cases and controls included in the analysis is shown in parenthesis. Results referred to the best p threshold (P_T) are shown, but they were consistent across different p thresholds tested. Nagelkerke R2 was reported on the liability scale considering a prevalence of 10.8% (Lim et al., 2018) for the MDD definition based on primary care records (≥ two GP codes depression), while for the other MDD phenotypes we considered the relative prevalence compared to ≥ two GP codes depression (e.g. ≥ one GP code depression was 1.59 times more common than ≥ two GP codes depression: 10.8% x 1.59 = 17.17%). After Bonferroni correction, alpha=2.16e-04. **(B)** Results of the association analyses between the PRS of major depressive disorder (MDD), bipolar disorder and schizophrenia with depression diagnosis in the EXCEED sample. After Bonferroni correction, alpha=1.52e-03.

Α

Base data	Target trait	Best P _T	E (SE)	P	OR (95% CI)	Nagelkerke R2
Major depressive disorder	≥ two GP codes	0.3	0.15 (0.008)	2.73e-71	1.16 (1.14-1.17)	0.0055
Bipolar disorder	depression (17,807 vs.	0.5	0.07 (0.008)	2.63e-17	1.07 (1.06-1.09)	0.0012
Schizophrenia	130,356)	1	0.09 (0.008)	4.30e-25	1.09 (1.07-1.11)	0.0018
Major depressive disorder	≥ one GP code	0.5	0.14 (0.006)	3.70e-100	1.15 (1.13-1.16)	0.0056
Bipolar disorder	depression (30,822 vs.	0.05	0.06 (0.006)	3.92e-21	1.06 (1.05-1.08)	0.0012
Schizophrenia	130,356)	0.3	0.08 (0.007)	4.98e-34	1.08 (1.07-1.10)	0.0018
Major depressive disorder	MHQ- depression	0.4	0.13 (0.007)	2.65e-84	1.14 (1.13-1.16)	0.0060
Bipolar disorder	(28,824 vs 83,203)	0.3	0.08 (0.007)	1.60e-31	1.09 (1.07-1.10)	0.0022
Schizophrenia		0.1	0.11 (0.007)	5.70e-50	1.11 (1.10-1.13)	0.0035
Major depressive disorder	ICD depression	0.2	0.15 (0.009)	2.61e-63	1.16 (1.14-1.18)	0.0044
Bipolar disorder	(13,172 vs 293,833)	0.3	0.08 (0.009)	2.89e-19	1.09 (1.07-1.11)	0.0013
Schizophrenia		1	0.08 (0.009)	4.54e-17	1.08 (1.06-1.10)	0.0011
Major depressive disorder	Smith depression	0.5	0.14 (0.008)	1.04e-74	1.15 (1.13-1.17)	0.0065
Bipolar disorder	(24,627 vs 64,476)	0.1	0.08 (0.008)	2.06e-27	1.09 (1.07-1.10)	0.0023
Schizophrenia		0.4	0.10 (0.008)	4.34e-41	1.11 (1.09-1.13)	0.0035
Major depressive disorder	Self-rep. depression	0.5	0.16 (0.007)	6.02e-106	1.17 (1.15-1.19)	0.0080
Bipolar disorder	(25,932 vs 85,361)	0.3	0.08 (0.007)	4.79e-28	1.08 (1.07-1.10)	0.0020
Schizophrenia		0.4	0.09 (0.007)	7.09e-36	1.10	0.0026

					(1.08-1.11)	
Major depressive disorder	Seen GP or psychiatrist	0.3	0.14 (0.003)	<1e-200	1.14 (1.14-1.15)	0.0065
Bipolar disorder	(135,947 vs 240,385)	0.4	0.08 (0.004)	2.32e-123	1.09 (1.08-1.09)	0.0024
Schizophrenia		0.4	0.10 (0.004)	1.38e-176	1.11 (1.10-1.11)	0.0034

В

Base data	Target trait	Best P _T	E (SE)	P	OR (95% CI)	Nagelkerke R ²
Major depressive	≥ 2 GP codes	0.2	0.23 (0.05)	6.05e-06	1.26	0.0124
disorder	for				(1.14-1.39)	
Bipolar disorder	depression	0.05	0.14 (0.05)	0.0060	1.15	0.0045
	(557 vs				(1.04-1.26)	
Schizophrenia	2,181)	0.05	0.11 (0.05)	0.0276	1.12	0.0029
					(1.01- 1.23)	

Supplementary Table 6: overlap between MDD defined according to primary care data (at least two diagnostic codes for depression) with other depression measures in UK Biobank. The overlap between participants having no diagnostic code for depression and participants having at least one diagnostic code for depression is reported for comparison. For each pair of depression phenotypes (non-primary care vs. primary care), the number of subjects having depression according to both / total number of subjects having both depression measures is reported and the corresponding percentage in parenthesis. A Fisher's exact test was used to compare the difference in overlap between those having at least two diagnostic codes for depression, one diagnostic code for depression and no diagnostic code for depression. * p values < Bonferroni corrected p value of 5e-3. GP=general practitioner.

Depression	Overlap with >= two	Overlap with one	Overlap with no	Overlap in those with at	Overlap in those with at
measure	depression diagnostic	depression diagnostic	depression diagnostic code	least two vs. at least one	least two vs. no
	codes in primary care	code in primary care	in primary care	depression diagnostic code	depression diagnostic code
ICD depression	3380/17024 (19.85%)	4863/31361 (15.51%)	2529/151412 (1.67%)	OR=1.28 (1.22-1.34),	OR=11.89 (11.25-12.55),
				p=5.69e-24*	p<2.2e-16*
Smith	3774/5013 (75.28%)	6312/9159 (68.92%)	9286/48234 (19.25%)	OR=1.09 (1.04-1.15),	OR=3.91 (3.73-4.10),
depression				p=1.14 e-03*	p<2.2e-16*
Self-reported	4047/4616 (87.67%)	6832/8412 (81.22%)	7594/53485 (14.20%)	OR=1.08 (1.02-1.14),	OR=6.17 (5.88-6.48),
depression				p=4.75e-03*	p<2.2e-16*
MHQ-defined	3217/4444 (72.39%)	5462/8180 (66.77%)	10834/54317 (19.95%)	OR=1.08 (1.02-1.15),	OR=3.63 (3.45-3.82),
depression				p=5.52e-03	p<2.2e-16*
Seen GP or	17301/19637 (88.10%)	29714/36128 (82.25%)	49892/185601 (26.88%)	OR=1.07 (1.04-1.10),	OR=3.28 (3.20-3.35),
psychiatrist for				p=1.35e-07*	p<2.2e-16*
depression					

Supplementary Table 7: Clinical and socio-demographic variables tested for association with treatment-resistant depression (TRD) compared to non-TRD in UKB; after Bonferroni correction alpha=1.39e-03. Logistic regression (beta (SE) or OR (95% CI) are reported for continuous and binary predictors, respectively) or Kruskal-Wallis test were used.

Variable	TRD n=2,430	Non-TRD n=15,951	Effect size or statistics	p-value	N missing
Number in household	577/2404	3726/15805 (23.57%)	OR = 0.98 (0.88 – 1.08)	0.65	172
(>1/total)	(24.00%)				
Leisure - social activities	1511/2421 (62.41%)	10377/15860 (65.43%)	OR = 0.89 (0.81 – 0.97)	0.007	100
(yes/total)					
Able to confide (where 0 is	3.14 (1.95)	3.34 (1.92)	Kruskal-Wallis chi2 = 23.52	1.25e-06	570
never and 5 is daily)					
Frequency of visits from	2.69 (1.23)	2.69 (1.17)	Kruskal-Wallis chi2=13.87	0.031	152
family/friends (0-7)					
Days/week of moderate	3.33 (2.45)	3.53 (2.40)	beta = -0.09 (0.02)	1.39e-04	1276
physical activity*					
Longstanding illness or	1534/2333 (65.75%)	6906/15409 (44.82%)	OR = 2.26 (2.06 – 2.49)	5.45e-64	639
disability yes/total **					
Education (% per category)***	College: 22.22%	College: 27.84%	OR = 0.64 (0.56 – 0.73)	1.61e-11	239
	A-levels: 11.79%	A-levels: 11.28%	OR = 0.84 (0.72 – 0.98)	0.029	
	0-levels-GCSEs: 22.72%	0-levels-GCSEs: 22.42%	OR = 0.80 (0.70 - 0.91)	0.00076	
	CSEs: 7.10%	CSEs: 6.62%	OR = 0.86 (0.71 – 1.05)	0.13	
	NVQ-HND-HNC: 6.15%	NVQ-HND-HNC: 7.09%	OR = 0.70 (0.58 - 0.85)	0.00033	
	Other professional title:	Other professional title:	OR = 0.77 (0.63 - 0.95)	0.014	
	5.23%	5.34%			
	None of the above: 24.79%	None of the above: 19.47%	Reference level		
Average household income £	<18K: 41.98%	<18K: 31.01%	Reference level		2793
(% per category)	18K-30.9K: 26.28%	18K-30.9K: 26.90%	OR = 0.72 (0.64 - 0.81)	4.62e-08	
	31K-51.9K: 20.67%	31K-51.9K: 24.17%	OR = 0.63 (0.56 - 0.72)	7.08e-13	
	52K-100K: 10.14%	52K-100K: 15.23%	OR = 0.49 (0.42 - 0.58)	5.81e-18	
	>100K: 0.94%	>100K: 2.69%	OR = 0.26 (0.16 – 0.41)	1.13e-08	
	Personality tra	its at baseline (available in the	whole UKB cohort)		
"Are you often troubled by	1366/2350 (58%)	7248/15419 (47%)	OR = 1.56 (1.43 – 1.71)	1.63e-23	612
feelings of guilt?" (yes/total)					
"Do you often feel lonely?"	1190/2369 (50.23%)	5819/15543 (37.43%)	OR = 1.69 (1.55 – 1.84)	3.98e-32	469
(yes/total)					

"Are your feelings easily hurt?" (yes/total)	1898/2365 (80.25%)	11383/15521 (73.34%)	OR = 1.48 (1.33 – 1.64)	1.01e-12	495
"Do you ever feel 'just miserable' for no reason?"	1984/2393 (82.91%)	11227/15650 (71.74%)	OR = 1.91 (1.71 – 2.14)	8.72e-30	338
(yes/total)					
"Are you an irritable person?" (yes/total)	1197/2297 (51.11%)	6278/15060 (41.69%)	OR = 1.52 (1.39 – 1.66)	8.44e-21	1024
"Does your mood often go up and down?" (yes/total)	2057/2397 (85.82%)	11571/15635 (74.01%)	OR = 2.12 (1.88 – 2.40)	9.97e-35	349
"Would you call yourself a nervous person?" (yes/total)	1201/2339 (51.35%)	5930/15385 (38.54%)	OR = 1.68 (1.54 – 1.84)	1.64e-31	657
Neuroticism score	7.97 (3.15)	6.35 (3.30)	beta = 0.46 (0.03)	3.0e-66	4089
"Would you describe yourself as someone who takes risks?" (yes/total)	585/2327 (25.14%)	3982/15245 (26.12%)	OR = 0.95 (0.86 – 1.05)	0.32	809

^{*} adjusted for age and sex; no longer significant if adjusted also for long-term disability or illness (p=3.29e-03)

** adjusted for age, sex, BMI and ever smoked

^{***} adjusted for age and sex

Supplementary Table 8: psychiatric comorbidities in patients with treatment-resistant depression (TRD) vs. non-TRD according to primary care records in UKB.

Comorbidities	TRD (n=2,430)	Non-TRD	Effect size	P value
		(n=15,951)		
Anxiety disorders	997 (41.03%)	4290 (26.89%)	OR=1.89 (1.73-2.07)	1.25e-45
Depression with	904 (37.20%)	4950 (31.03%)	OR=1.32 (1.20-1.44)	1.30e-09
anxiety				
Obsessive-	60 (2.47%)	132 (0.083%)	OR=3.03 (2.23-4.13)	1.69e-12
compulsive				
disorder				
Somatoform	195 (8.02%)	860 (5.39%)	OR=1.53 (1.30-1.80)	2.43e-07
disorders				
Stress-related	196 (8.07%)	1014 (6.36%)	OR=1.29 (1.10-1.52)	0.0016
disorders				
Eating disorders	45 (1.85%)	127 (0.080%)	OR=2.35 (1.67-3.31)	1.02e-06
Sleep disorders	83 (3.42%)	304 (1.91%)	OR=1.82 (1.42-2.33)	1.93e-06
Personality	55 (2.26%)	147 (0.092%)	OR=2.49 (1.82-3.40)	1.09e-08
disorders				
Self-harm/suicidal	132 (5.43%)	438 (2.28%)	OR=2.03 (1.67-2.48)	2.99e-12
behaviours				

Supplementary Table 9: frequency of psychotropic drug combinations (**A**), type of antidepressant drug combinations (**B**) and combinations based on drug classes (**C**) in UKB. Antidepressant augmentation with any antipsychotic or a mood stabilizer among lithium, valproate, lamotrigine and pregabalin were considered in patients with TRD and non-TRD. Only combinations prescribed for longer than 30 days were considered. When considering specific drug or class combinations, only those prescribed to > 15 subjects were considered. Fisher's exact test was used for comparisons because of the small size of some of the groups. Bonferroni corrected p values was 2.38e-03 and 1.43e-03 for the comparisons in B and C, respectively. * significant difference between TRD and non-TRD.

Α

Drug combination	TRD (n=2430)	Non-TRD (n=15951)	Statistics
Antidepressant	1128 (46.42%)	1307 (8.19%)	OR=5.66 (5.17-6.21),
combination			p=4.03e-289*
Augmentation with	354 (14.57%)	576 (3.61%)	OR=4.03 (3.50-4.65),
antipsychotic			p=2.95e-75*
Augmentation with	326 (13.42%)	406 (2.55%)	OR=5.27 (4.51-6.15),
mood stabilizer			p=4.33e-90*

В

Drug combination	TRD	Non-TRD	Statistics
amitriptyline-	198 (17.55%)	266 (20.35%)	OR=0.86 (0.70-1.06), p=0.15
citalopram			
amitriptyline-	144 (12.77%)	245 (18.75%)	OR=0.68 (0.54-0.85),
fluoxetine			p=6.56e-04*
amitriptyline-	73 (6.47%)	49 (3.75%)	OR=1.73 (1.17-2.55),
mirtazapine			p=3.87e-03
amitriptyline-	32 (2.84%)	39 (2.98%)	OR=0.95 (0.57-1.57), p=0.90
paroxetine			
amitriptyline-	16 (1.42%)	12 (0.92%)	OR=1.54 (0.68-3.59), p=0.26
duloxetine			
amitriptyline-	112 (9.93%)	121 (9.26%)	OR=1.07 (0.81-1.42), p=0.63
sertraline			
amitriptyline-	58 (5.14%)	8 (3.67%)	OR=8.39 (3.97-20.44),
venlafaxine			p=4.69e-12*
citalopram-	20 (1.77%)	7 (0.54%)	OR=3.31 (1.34-9.30),
dosulepin			p=5.62e-03
citalopram-	60 (5.32%)	30 (2.30%)	OR=2.32 (1.46-3.75),
fluoxetine			p=1.51e-04*
citalopram-	50 (4.43%)	58 (4.44%)	OR=1 (0.66-1.50), p=1
mirtazapine			
citalopram-	41 (3.63%)	32 (2.45%)	OR=1.48 (0.91-2.45), p=0.12
sertraline			
citalopram-	16 (1.42%)	6 (0.05%)	OR=3.09 (1.14-9.67), p=0.017
venlafaxine			
fluoxetine-	33 (2.93%)	25 (1.91%)	OR=1.53 (0.88-2.70), p=0.14
mirtazapine			
fluoxetine-sertraline	49 (4.34%)	11 (0.084%)	OR=5.16 (2.63-11.06),
			p=4.83e-08*

mirtazapine-	46 (4.08%)	38 (2.91%)	OR=1.40 (0.89-2.23), p=0.15
sertraline			
mirtazapine-	82 (7.27%)	65 (4.97%)	OR=1.46 (1.03-2.08), p=0.027
venlafaxine			
trazodone-	13 (1.15%)	18 (1.38%)	OR=0.84 (0.38-1.82), p=0.72
citalopram			
trazodone-	14 (1.24%)	19 (1.45%)	OR=0.85 (0.39-1.81), p=0.73
fluoxetine			
trazodone-	16 (1.42%)	12 (0.092%)	OR=1.54 (0.68-3.59), p=0.26
venlafaxine			
venlafaxine-	16 (1.42%)	12 (0.092%)	OR=1.54 (0.68-3.59), p=0.26
citalopram			
venlafaxine-	16 (1.42%)	3 (0.022%)	OR=6.17 (1.76-33.17),
sertraline			p=9.35e-04*

С

Drug combination	TRD	Non-TRD	Statistics	
SNRI-NaSSA	97 (5.93%)	64 (4.45%)	OR=1.33 (0.95-1.87), p=0.09	
SNRI-SARI	29 (1.78%)	23 (1.60%)	OR=1.11 (0.62-2.01), p=0.78	
SNRI-SNRI	16 (0.98%)	2 (0.14%)	OR=7.09 (1.65-63.08),	
			p=0.0031	
SSRI-NaSSA	165 (10.08%)	128 (8.91%)	OR=1.13 (0.88-1.45), p=0.33	
SSRI-phenothiazine	19 (1.16%)	8 (0.06%)	OR=2.08 (0.87-5.52), p=0.08	
SSRI-SARI	70 (4.28%)	68 (4.73%)	OR=0.90 (0.63-1.29), p=0.60	
SSRI-SNRI	126 (7.70%)	59 (4.11%)	OR=1.87 (1.35-2.62),	
			p=7.33e-05*	
SSRI-SSRI	195 (11.91%)	105 (7.31%)	OR=1.63 (1.27-2.11),	
			p=9.75e-05*	
TCA-NaSSA	94 (5.74%)	63 (4.38%)	OR=1.31 (0.93-1.85), p=0.12	
TCA-SARI	41 (2.50%)	26 (1.81%)	OR=1.38 (0.82-2.37), p=0.22	
TCA-SNRI	119 (7.27%)	99 (6.89%)	OR=1.06 (0.79-1.41), p=0.73	
TCA-SSRI	594 (36.29%)	760 (52.89%)	OR=0.69 (0.60-0.78),	
			p=9.17e-09*	
TCA-TCA	72 (4.40%)	32 (2.23%)	OR=1.97 (1.28-3.12),	
			p=0.0013*	
NaSSA-atypical AP	63 (10.29%)	75 (9.99%)	OR=1.03 (0.71-1.49), p=0.93	
NaSSA-typical AP	26 (4.25%)	29 (3.86%)	OR=1.10 (0.62-1.96), p=0.78	
SARI-atypical AP	20 (3.27%)	15 (2.0%)	OR=1.64 (0.79-3.47), p=0.17	
SARI-typical AP	26 (4.25%)	17 (2.26%)	OR=1.88 (0.97-3.72), p=0.06	
SNRI-atypical AP	66 (10.78%)	84 (11.19%)	OR=0.96 (0.68-1.37), p=0.96	
SNRI-typical AP	49 (8.01%)	46 (6.13%)	OR=1.31 (0.84-2.03), p=0.24	
SSRI-atypical AP	97 (15.85%)	124 (16.51%)	OR=0.96 (0.71-1.29), p=0.83	
SSRI-typical AP	131 (21.41%)	215 (28.63%)	OR=0.75 (0.58-0.96), p=0.021	
TCA atypical AP	40 (6.54%)	35 (4.60%)	OR=1.40 (0.86-2.30), p=0.16	
TCA typical AP	94 (15.36%)	111 (14.78%)	OR=0.82 (0.76-1.41), p=0.82	
NaSSA-lithium	31 (6.11%)	18 (3.11%)	OR=1.97 (1.05-3.78), p=0.028	
NaSSA-pregabalin	46 (9.07%)	28 (4.84%)	OR=1.88 (1.13-3.16), p=0.011	

SARI-lithium	16 (3.16%)	8 (1.38%)	OR=2.28 (0.91-6.21), p=0.06	
SNRI-lithium	46 (9.07%)	36 (6.22%)	OR=1.46 (0.91-2.36), p=0.11	
SNRI-pregabalin	47 (9.27%)	43 (7.43%)	OR=1.25 (0.79-1.97), p=0.32	
SSRI-lamotrigine	23 (4.54%)	15 (2.59%)	OR=1.75 (0.86-3.65), p=0.10	
SSRI-lithium	61 (12.03%)	27 (4.66%)	OR=2.58 (1.59-4.29),	
			p= 5.31e-05*	
SSRI-pregabalin	134 (26.43%)	148 (25.56%)	OR=1.03 (0.79-1.36), p=0.84	
SSRI-valproate	27 (5.33%)	25 (4.32%)	OR=1.23 (0.68-2.25), p=0.48	
TCA-lithium	43 (8.48%)	32 (5.53%)	OR=1.53 (0.93-2.55), p=0.09	
TCA-pregabalin	84 (16.57%)	119 (2.06%)	OR=0.80 (0.59-1.10), p=0.17	
TCA-valproate	21 (4.12%)	8 (1.38%)	OR=2.99 (1.26-7.89),	
			p=0.0076	

Supplementary Table 12: results of the association analyses between the PRS of interest and the risk of treatment-resistant depression (TRD) vs. non-TRD in UKB. Nagelkerke R2 is reported on the observed scale since the comparison is referred to cases only. *significant results after Bonferroni correction (p=5.81e-04). $P_T = p$ threshold.

Base data	Best P _⊤	E (SE)	Р	OR (95% CI)	Nagelkerke R2
Major depressive	0.001	0.05 (0.02)	0.028	1.05 (1.01-1.10)	5.36e-04
disorder					
Attention-deficit	0.2	0.08 (0.02)	4.38e-04*	1.09 (1.04-1.14)	1.38e-03
hyperactivity					
disorder					
Schizophrenia	0.1	0.04 (0.02)	0.14	1.04 (0.99-1.09)	2.48e-04
Bipolar disorder	0.01	0.04 (0.02)	0.07	1.04 (0.99-1.09)	3.74e-04
Neuroticism	0.01	0.06 (0.02)	7.42e-03	1.06 (1.02-1.11)	7.98e-04
Subjective well-being	0.2	-0.08 (0.02)	1.32e-03	0.93 (0.89-0.97)	1.15e-03
Intelligence	0.1	-0.09 (0.02)	3.08e-04*	0.92 (0.87-0.96)	1.45e-03
Childhood IQ	0.05	-0.02 (0.02)	0.50	0.98 (0.94-1.03)	5.02e-05